| Form 144 Filer Information |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144
NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 | |
FORM 144 |
144: Filer Information
| Filer CIK | 0001551891 |
| Filer CCC | XXXXXXXX |
| Is this a LIVE or TEST Filing? |  LIVE
 TEST
|
Submission Contact Information | |
| Name | |
| Phone | |
| E-Mail Address |
144: Issuer Information
| Name of Issuer | ARS Pharmaceuticals, Inc. |
| SEC File Number | 001-39756 |
| Address of Issuer | 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CALIFORNIA 92130 |
| Phone | 858-771-9307 |
| Name of Person for Whose Account the Securities are To Be Sold | Shawver Laura |
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account
the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given
as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales
for the account of the person filing this notice.
| |
| Relationship to Issuer | Director |
144: Securities Information
| Title of the Class of Securities To Be Sold | Name and Address of the Broker | Number of Shares or Other Units To Be Sold | Aggregate Market Value | Number of Shares or Other Units Outstanding | Approximate Date of Sale | Name the Securities Exchange | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COMMON | Merrill Lynch Get the next $SBTX alert in real time by email101 S. Ellsworth Ave. 4th Floor San Mateo Chat with this insightSave time and jump to the most important pieces. Recent Analyst Ratings for |
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/4/2022 | $25.00 → $3.50 | Buy → Neutral | Goldman |
| 4/1/2022 | $25.00 → $1.80 | Outperform → Mkt Perform | SVB Leerink |
| 4/1/2022 | $32.00 → $6.00 | Buy → Hold | Stifel |
| 4/1/2022 | Buy → Neutral | H.C. Wainwright | |
| 11/12/2021 | $42.00 → $25.00 | Outperform | SVB Leerink |
| 8/16/2021 | $46.00 → $49.00 | Outperform | SVB Leerink |
SEC Form SC 13G/A filed by Silverback Therapeutics Inc. (Amendment)
SC 13G/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
SEC Form SC 13D/A filed by Silverback Therapeutics Inc. (Amendment)
SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
SEC Form SC 13D/A filed by Silverback Therapeutics Inc. (Amendment)
SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
Lowenthal Richard E gifted 2,100,000 shares and received a gift of 2,100,000 shares, decreasing direct ownership by 20% to 4,126,822 units (SEC Form 4)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
SEC Form 4 filed by Karas Eric
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
Tanimoto Sarina gifted 2,100,000 shares and received a gift of 2,100,000 shares, decreasing direct ownership by 24% to 3,276,854 units (SEC Form 4)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
Data from Pivotal Clinical Trials to be Presented in Five Poster Presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific Meeting Data Support New Drug Application for neffy®, Currently Under Review with U.S. FDA SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) (ARS or the Company), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced that positive clinical data supporting neffy® (previously referred to as ARS-1), the potential first non-injectable medicine for treatment of alle
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
Over $280 Million in Combined Cash and Securities and at least Three Years Operating Runway to Support Launch and Commercialization of neffy® in the U.S., if Approved neffy® NDA Currently Under FDA Review; PDUFA Anticipated Mid-2023 MAA validated in the European Union Under Review SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) (ARS or the Company), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the closing of its merger with Silverback Therapeutics, Inc. (Silverback). This follows the satisfaction of all cus
Silverback Therapeutics, Inc. announces the FDA's acceptance of ARS Pharmaceuticals' NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
neffy has potential to be the first non-injectable medicine indicated to treat allergic reactions (type I) including anaphylaxis in the U.S., if approved Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback") today announced that the U.S. Food and Drug Administration (FDA) has accepted for review ARS Pharmaceuticals, Inc.'s (ARS Pharma) New Drug Application (NDA) for neffy for the emergency treatment of allergic reactions (type I) including anaphylaxis in adults and children ≥30 kg (66 lbs). If approved by the FDA, neffy would be the first non-injectable treatment available to patients with allergic reactions (type I) including anaphylaxis. The FDA has assigned a Prescription Drug U
ARS Pharmaceuticals Closes Merger With Silverback Therapeutics; neffy NDA Currently Under FDA Review; PDUFA Anticipated Mid-2023 MAA Validated In The European Union Under Review
Over $280 Million in Combined Cash and Securities and at least Three Years Operating Runway to Support Launch and Commercialization of neffy® in the U.S., if Approved neffy® NDA Currently Under FDA Review; PDUFA Anticipated Mid-2023 MAA validated in the European Union Under Review SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) (ARS or the Company), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the closing of its merger with Silverback Therapeutics, Inc. (Silverback). This follows the satisfaction of all cus
Silverback Therapeutics Announced FDA's Acceptance of ARS Pharmaceuticals' NDA for Neffy (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) Including Anaphylaxis
Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback") today announced that the U.S. Food and Drug Administration (FDA) has accepted for review ARS Pharmaceuticals, Inc.'s (ARS Pharma) New Drug Application (NDA) for neffy for the emergency treatment of allergic reactions (type I) including anaphylaxis in adults and children ≥30 kg (66 lbs). If approved by the FDA, neffy would be the first non-injectable treatment available to patients with allergic reactions (type I) including anaphylaxis. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date that is anticipated in mid-2023. "The FDA acceptance of our NDA for neffy is a major milestone in our efforts to bring
This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday
Gainers AMTD Digital Inc. (NYSE:HKD) climbed 234.7% to settle at $68.00 on Friday amid continued post-IPO volatility. Pagaya Technologies Ltd. (NASDAQ:PGY) shares jumped 118.9% to close at $11.71 on Friday. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022. AMTD IDEA Group (NYSE:AMTD) gained 103.7% to close at $2.20. The company owns at least 88% stake in recent IPO AMTD Digital. Kidpik Corp. (NYSE:PIK) surged 66.4% to close at $2.48. Yoshitsu Co., Ltd (NASDAQ:TKLF) jumped 48.4% to close at $2.30 after the company announced it will acquire Tokyo Lifestyle Limited for approximately $2.8 million. ToughBuilt Industries, Inc. (NASDAQ:TBLT) rose 39.5% to clo
Silverback Therapeutics Announces the Appointment of Dr. Maria Koehler to its Board of Directors
SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the appointment of Maria Koehler, M.D., Ph.D. to Silverback’s Board of Directors. “On behalf of the board of directors and senior management team at Silverback, I am pleased to welcome Maria to the board,” said Peter Thompson, M.D., Co-founder and Chair of the Silverback Board of Directors. “Maria is an accomplished biopharmaceutical ve
Fitzpatrick Alexander A bought $319,954 worth of shares (86,258 units at $3.71), increasing direct ownership by 2,905% to 89,227 units (SEC Form 4)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
SEC Form 4: Ra Capital Management, L.P. bought $8,183,526 worth of shares (2,700,000 units at $3.03)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
Silverback Therapeutics and ARS Pharmaceuticals Announce Merger
Transaction to support potential commercialization of neffy™, ARS's needle-free epinephrine nasal spray Well-funded with at least three years of operating runway expected Companies to host conference call today, July 21, 2022, at 5:00 p.m. ET Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback") and ARS Pharmaceuticals, Inc. ("ARS") today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS's investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anap
Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results
- Strategic realignment to focus resources on SBT8230 for chronic hepatitis B virus (cHBV) and discovery pipeline by discontinuing SBT6050 and SBT6290 clinical oncology programs - On track to complete a Phase 1 regulatory submission for SBT8230 in the fourth quarter of 2022 - Silverback to restructure workforce to support prioritized development, reduce operating expense, and extend cash runway - Estimated cash runway extended into the second half of 2026 Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chron
Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressing Solid Tumors
– Proof-of-mechanism established with activation of myeloid and T/NK cells, and evidence of SBT6050 payload localization in the tumor microenvironment – – SBT6050 demonstrated a manageable safety profile with adverse events consistent with on-mechanism immune activation, both as a monotherapy or in combination with pembrolizumab – – Early signals of anti-tumor activity observed in a heavily pre-treated, heterogeneous population – – Management to host conference call today at 6:30 AM ET – Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissu
Silverback Therapeutics downgraded by Goldman with a new price target
Goldman downgraded Silverback Therapeutics from Buy to Neutral and set a new price target of $3.50 from $25.00 previously
Silverback Therapeutics downgraded by SVB Leerink with a new price target
SVB Leerink downgraded Silverback Therapeutics from Outperform to Mkt Perform and set a new price target of $1.80 from $25.00 previously
Silverback Therapeutics downgraded by Stifel with a new price target
Stifel downgraded Silverback Therapeutics from Buy to Hold and set a new price target of $6.00 from $32.00 previously
SEC Form 10-Q filed by Silverback Therapeutics Inc.
10-Q - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
Silverback Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
Silverback Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)